Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States: Health services research and quality improvement

Jorge J Castillo; Keri  Yang; Rongzhe Liu; Yu Wang; Aileen Cohen; Todd M Zimmerman; Qian Zhao; Gijs  van de Wetering; Xin Gao; Boxiong Tang

doi:10.1200/JCO.2021.39.15_suppl.e18856

Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States: Health services research and quality improvement

Jorge J Castillo, Keri Yang, Rongzhe Liu, Yu Wang, Aileen Cohen, Todd M Zimmerman, Qian Zhao, Gijs van de Wetering, Xin Gao, Boxiong Tang

Health Sciences

Research output: Contribution to journal › Meeting abstract

Abstract

Meeting Abstract | 2021 ASCO Annual Meeting I

Original language	English
Pages (from-to)	e18856
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	39
Issue number	Issue 15 supplement
DOIs	https://doi.org/10.1200/JCO.2021.39.15_suppl.e18856
Publication status	Published - 2021

Access to Document

10.1200/JCO.2021.39.15_suppl.e18856

Cite this

Castillo, J. J., Yang, K., Liu, R., Wang, Y., Cohen, A., Zimmerman, T. M., Zhao, Q., van de Wetering, G., Gao, X., & Tang, B. (2021). Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States: Health services research and quality improvement. Journal of Clinical Oncology, 39(Issue 15 supplement ), e18856. https://doi.org/10.1200/JCO.2021.39.15_suppl.e18856

@article{563ad1c4b6e540caa78791c901a3a314,

title = "Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstr{\"o}m macroglobulinemia in the United States: Health services research and quality improvement",

abstract = "Meeting Abstract | 2021 ASCO Annual Meeting I",

author = "Castillo, {Jorge J} and Keri Yang and Rongzhe Liu and Yu Wang and Aileen Cohen and Zimmerman, {Todd M} and Qian Zhao and {van de Wetering}, Gijs and Xin Gao and Boxiong Tang",

year = "2021",

doi = "10.1200/JCO.2021.39.15_suppl.e18856",

language = "English",

volume = "39",

pages = "e18856",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "Issue 15 supplement ",

}

Castillo, JJ, Yang, K, Liu, R, Wang, Y, Cohen, A, Zimmerman, TM, Zhao, Q, van de Wetering, G, Gao, X & Tang, B 2021, 'Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States: Health services research and quality improvement', Journal of Clinical Oncology, vol. 39, no. Issue 15 supplement , pp. e18856. https://doi.org/10.1200/JCO.2021.39.15_suppl.e18856

Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States: Health services research and quality improvement. / Castillo, Jorge J; Yang, Keri ; Liu, Rongzhe et al.
In: Journal of Clinical Oncology, Vol. 39, No. Issue 15 supplement , 2021, p. e18856.

Research output: Contribution to journal › Meeting abstract

TY - JOUR

T1 - Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States

T2 - Health services research and quality improvement

AU - Castillo, Jorge J

AU - Yang, Keri

AU - Liu, Rongzhe

AU - Wang, Yu

AU - Cohen, Aileen

AU - Zimmerman, Todd M

AU - Zhao, Qian

AU - van de Wetering, Gijs

AU - Gao, Xin

AU - Tang, Boxiong

PY - 2021

Y1 - 2021

N2 - Meeting Abstract | 2021 ASCO Annual Meeting I

AB - Meeting Abstract | 2021 ASCO Annual Meeting I

U2 - 10.1200/JCO.2021.39.15_suppl.e18856

DO - 10.1200/JCO.2021.39.15_suppl.e18856

M3 - Meeting abstract

SN - 0732-183X

VL - 39

SP - e18856

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - Issue 15 supplement

ER -